Olema Pharmaceuticals plans to present mature data on the Palazestrant/ribociclib combination study at ESMO 2025.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Olema Pharmaceuticals plans to present mature data on the Palazestrant/ribociclib combination study at ESMO 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Olema Pharmaceuticals (United States)
company in San Francisco, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireOlema Oncology Reports Second Quarter 2025 Financial and Operating Results Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 tri